Skip to main content
Article thumbnail
Location of Repository

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC

By Pranshu eBansal, Diaa eOsman, Gregory eGan, George R Simon and Yanis eBoumber

Abstract

Lung adenocarcinoma is the most common subtype of non-small cell lung cancer (NSCLC). With the discovery of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements and effective targeted therapies, therapeutic options are expanding for patients with lung adenocarcinoma. Here, we review novel therapies in non-squamous NSCLC, which are directed against oncogenic targets, including EGFR, ALK, ROS1, BRAF, MET, human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor receptor 2 (VEGFR2), RET and NTRK. With the rapidly evolving molecular testing and development of new targeted agents, our ability to further personalize therapy in non-squamous NSCLC is rapidly expanding

Topics: EGFR, BRAF, ALK, NSCLC, c-Met, ROS1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: Frontiers Media S.A.
Year: 2016
DOI identifier: 10.3389/fonc.2016.00112
OAI identifier: oai:doaj.org/article:43adc917f569428c930e255ef6c042d5
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2234-943X (external link)
  • http://journal.frontiersin.org... (external link)
  • https://doaj.org/article/43adc... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.